Oral dosage forms including an antiplatelet agent and an acid inhibitor

1. A single unit oral dosage form comprising: a) an adenosine diphosphate (ADP) or P 2 Y 12 antagonist or a pharmaceutically acceptable salt or enantiomer thereof, in a therapeutically effective amount to provide antiplatelet activity; and b) a proton pump inhibitor (PPI) or a pharmaceutically acceptable salt or enantiomer thereof, in a therapeutically effective amount to prevent or reduce a gastrointestinal disorder associated with use of said ADP or P 2 Y 12 antagonist or said ADP or P 2 Y 12 antagonist and aspirin, wherein said PPI, is enterically coated.

2. The single unit oral dosage form of claim 1 , wherein said ADP or P 2 Y 12 antagonist or pharmaceutically acceptable salt or enantiomer thereof is clopidogrel and said PPI or pharmaceutically acceptable salt or enantiomer thereof is omeprazole.

3. The single unit oral dosage form of claim 2 , wherein the clopidogrel or pharmaceutically acceptable salt or enantiomer thereof is a powder and the omeprazole or pharmaceutically acceptable salt or enantiomer thereof is enterically coated.

4. The single unit oral dosage form of claim 3 , wherein the clopidogrel or pharmaceutically acceptable salt or enantiomer thereof and omeprazole or pharmaceutically acceptable salt or enantiomer thereof are disposed within a capsule.

5. The single unit oral dosage form of claim 2 , wherein the clopidogrel or pharmaceutically acceptable salt or enantiomer thereof is present in an amount of 20-200 mg and the omeprazole or pharmaceutically acceptable salt or enantiomer thereof is present in an amount of about 10-100 mg.

6. The single unit oral dosage form of claim 2 , wherein the clopidogrel or pharmaceutically acceptable salt or enantiomer thereof is present in an amount of 20-200 mg and the omeprazole or pharmaceutically acceptable salt or enantiomer thereof is present in an amount of about 10-100 mg.

7. The single unit oral dosage form of claim 4 , wherein the clopidogrel or pharmaceutically acceptable salt or enantiomer thereof is present in an amount of 20-200 mg and the omeprazole or pharmaceutically acceptable salt or enantiomer thereof is present in an amount of about 10-100 mg.

8. The single unit oral dosage form of claim 5 , wherein the clopidogrel or pharmaceutically acceptable salt or enantiomer thereof is present in an amount of 75 mg and the omeprazole or pharmaceutically acceptable salt or enantiomer thereof is present in an amount of 20 mg.

9. The single unit oral dosage form of claim 6 , wherein the clopidogrel or pharmaceutically acceptable salt or enantiomer thereof is present in an amount of 75 mg and the omeprazole or pharmaceutically acceptable salt or enantiomer thereof is present in an amount of 20 mg.

10. The single unit oral dosage form of claim 7 , wherein the clopidogrel or pharmaceutically acceptable salt or enantiomer thereof is present in an amount of 75 mg and the omeprazole or pharmaceutically acceptable salt or enantiomer thereof is present in an amount of 20 mg.

11. A combination of the single unit oral dosage form of any one of claims 1 , 2 , 3 , 4 , or 5 - 10 , together with an oral dosage form comprising aspirin.

12. The single unit oral dosage form of any one of claims 1 , 2 , 3 , 4 , or 5 - 10 , further comprising aspirin.

13. The single unit oral dosage form of any one of claims 1 , 2 , 3 , 4 , or 5 - 10 , wherein said single unit oral dosage form excludes a non-aspirin non-steroidal anti-inflammatory drug (NSAID).

14. A method of treating a patient who is in need of antiplatelet therapy and does not have symptoms of gastrointestinal bleeding or a gastrointestinal ulcer, comprising orally administering to said patient the single unit oral dosage form of any one of claims 5 - 10 .

15. A method of treating a patient who is in need of antiplatelet therapy and does not have symptoms of gastrointestinal bleeding or a gastrointestinal ulcer, comprising orally administering to said patient the combination of oral dosage forms recited in claim 11 .

16. A method of treating a patient who is in need of antiplatelet therapy and does not have symptoms of gastrointestinal bleeding or a gastrointestinal ulcer, comprising orally administering to said patient the single unit oral dosage form recited in claim 12 .